Plandai Biotechnology Announces Origine 8 Wins Pre

Phytofare® Based Nutriceutical Wins Judges Choice for 2018

LONDON, UK, May 24, 2018 (GLOBE NEWSWIRE) -- Plandai Biotechnology, Inc. (PLPL) (“Plandai” or “the Company”), producer of the highly bioavailable Phytofare® catechin complex, today announced that Origine 8™ , a product derived from Phytofare®, has been awarded the Judges Choice award at the  2018 Natural & Organic Products Europe  expo.  Origine 8™ is comprised of all eight Phytofare® catechins entrapped in nutrient-protective liposomes and  produced exclusively for Coyne Healthcare, a nutriceutical and food supplement company based in South Africa. 

Natural & Organic Products Europe  is Europe’s biggest trade show for natural & organic products, making it the ‘must attend’ event for buyers of natural health and living products, natural and organic food & drink as well as natural beauty & personal care products. Awards are given out annually highlighting the very best products, individuals and stores throughout the continent.

Kevin Coyne, President of Coyne Healthcare, commented, “We were thrilled to win the Judges Choice award in our first year exhibiting at the Natural & Organic Products expo.  It is a testimony to the incredible product that we have developed with Plandaí.  There is simply nothing on the market that rivals what we can offer in the way of green tea catechins and their amazing anti-oxidant and preventative properties.”

Callum Cottrell-Duffield, Chief Operating Officer of Plandaí, added, “Coyne Healthcare has been a tremendous partner to us and we could not be prouder of their success with Origine 8™.  This award is a validation of their hard work and foresight in being among the first to recognize the nutraceutical benefits of using highly-bioavailable catechins as a daily supplement.  We look forward to their continued success throughout Europe and as they expand into the North American markets.”

 About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing live green tea on its farms in South Africa to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit  http://www.plandaibiotech.com .

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at  http://www.sec.gov .

Contact Information Hayden IR (917) 658-7878 hart@haydenir.com  Marlin Molinaro Marmel Communications, LLC (828) 669-0616 mmolinarofc@aol.com